Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
Clinical trial NCT05636293 · COMPLETED
Trial details
- NCT number
- NCT05636293
- Sponsor
- Massachusetts General Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2025-12-09
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.